遺伝子編集ツールの世界市場-2023年～2030年

概要

世界の遺伝子編集ツール市場は、2022年に58億米ドルに達し、2023年から2030年の予測期間中にCAGR 18.7％で成長し、2030年には220億米ドルに達すると予想されています。

CRISPRセラピューティクスとバーテックス・ファーマシューティカルズは、ケリーCRISPR＆遺伝子編集技術ETFの一員であり、CRISPRに基づく米国初の市販治療薬を今年発売する予定です。Exa-celと呼ばれるこの治療薬は、鎌状赤血球症とβサラセミアに対する遺伝子編集治療薬で、CRISPRを利用した医薬品として初めて市場に出る可能性があります。

FDAは鎌状赤血球症の優先審査を認めており、2023年12月8日までに決定が下される見込みです。承認されれば、ライフサイエンス産業革命における重要なマイルストーンとなり、将来の遺伝子編集プログラムに期待をかけることができます。バーテックス社はExa-celの開発、製造、商業化を世界に主導し、プログラムの費用と利益をCRISPRセラピューティクス社と60/40で世界的に分担しています。

遺伝子編集ツールは、科学者に生物の遺伝物質を正確に改変する力を与える画期的な技術です。CRISPR-Cas9、TALEN、ZFNを含むこれらのツールにより、研究者は特定のDNA配列を前例のないレベルで正確に挿入、削除、改変することができます。

この画期的な技術は、医療、農業、バイオテクノロジーなどさまざまな分野に広く影響を及ぼし、標的治療の開発、遺伝子組み換え生物の作製、科学的知識の向上を可能にします。遺伝子編集ツールは、遺伝性疾患に対処し、作物の収量を向上させ、遺伝学と個別化医療の未来を形作るイノベーションを推進する計り知れない可能性を秘めています。

さらに、様々な産業における遺伝子編集ツールの急速な進歩と採用、および市場プレイヤーによる投資の増加が、予測期間にわたって市場を牽引すると予想される要因です。

ダイナミクス

血液疾患に対するin vivo RNAベース遺伝子編集モデル開発研究の増加が市場成長を牽引すると期待される

2023年7月27日、フィラデルフィア小児病院（CHOP）とペンシルベニア大学ペレルマン医学部の研究チームが、血液疾患の治療のために遺伝子編集ツールを体内に直接投与するモデルの作成に成功しました。この開発により、体内の病的な血液細胞を直接改変する道が開かれ、血液疾患の治療に大きなブレークスルーがもたらされる可能性があります。

研究者らは実験において、CRISPRベースの遺伝子編集ツールを用いてマウスの血液細胞の遺伝子を改変し、その結果は有望でした。この画期的な成果は、生体外遺伝子編集が不要になる可能性があるという点で特に重要です。このプロセスでは、細胞を体外に取り出し、研究室で編集した後、体内に戻す必要があります。一方、生体内での遺伝子編集は、血液疾患の治療において、より効率的で侵襲の少ないアプローチとなる可能性があります。

したがって、上記の要因により、予測期間中、市場は拡大すると予想されます。

悪性非ホジキンリンパ腫に対するPD-1ノックアウトによるCD19を標的とした同種CRISPRベースCAR-T療法の臨床成績の増加が市場成長を促進すると予想されます。

2022年12月、Caribou Biosciences社は、治療が困難な侵攻性非ホジキンリンパ腫のCD19を標的とする同種CRISPRベースCAR-T療法の米国での試験で良好な結果を発表しました。この治療法は、がん細胞が免疫系を回避するために利用することがあるPD-1遺伝子を無効にする第二の遺伝子改変も特徴としています。この治療法は概して忍容性が高く、安全性プロファイルも許容範囲内でした。

参加者6人を対象とした第1相試験では、最初に全員が完全寛解を示しました。参加者のうち2人は1年後も病気の徴候がなく、現在も試験でモニターされています。カリブー・バイオサイエンスの製品は、この初期データに基づいて、FDAからRMAT（再生医療先進治療）とファスト・トラックの指定を受けた。これは遺伝子編集とがん治療の分野における画期的な開発です。

CD19を標的とし、PD-1を不活性化するこの治療法の成功は、非ホジキンリンパ腫を対象とした第1相試験において、有望な安全性と有効性の結果を示しています。CRISPR技術を用いて遺伝子を改変する能力は、個別化がん治療や標的がん治療の新たな可能性を開くものです。これらの知見を確認し、このアプローチの長期的な有効性を判断するには、さらなる調査と臨床試験が必要です。

遺伝子編集の分野は日進月歩であり、この画期的な治療法は、個別化された標的治療によってがん治療を一変させる可能性を秘めています。この治療法の長期的有効性を確立し、がん患者のための精密医療の新時代を切り開くには、さらなる調査と臨床試験が不可欠です。

希少作物における遺伝子編集の規制課題が市場成長の妨げになると予想されます。

農作物における遺伝子編集は、国や地域によって規制環境が異なるため、希少作物における遺伝子編集技術の採用や導入の妨げになる可能性があります。ある種の希少作物は、その独特な遺伝子構成や限られた商業的価値のために、さらなる規制上の障害に直面する可能性があります。

例えば、欧州連合（EU）は遺伝子編集作物や食品を規制する厳しいアプローチをとっており、そのイントロダクションを事実上禁止しています。対照的に、米国は規制の枠組みが緩やかです。このような違いは、異なる地域で事業を展開する企業や研究者にとって課題となります。

EUの厳しい規制は、欧州司法裁判所（ECJ）が2018年に下した、遺伝子編集は2001年の遺伝子組み換え作物指令の下で規制されなければならないという判決に由来しており、この指令は、別の種の遺伝子を使用する遺伝子組み換え作物（トランスジェニック作物など）を制限しています。したがって、遺伝子編集作物や食品はEUでは禁止されています。

しかし、2022年9月、EU農相は、植物のDNAをより簡単かつ迅速に改変できる精密技術（シスジェニックス）の利点を認め、遺伝子編集に関する規則の改正を議論しました。そのため、EUや米国など国や地域によって規制の枠組みが異なることは、作物への遺伝子編集技術の普及と導入に課題をもたらす可能性があります。ハーモナイゼーションによる規制の合理化は、遺伝子編集作物の効率的な開発と商業化を助け、よりアクセスしやすく、世界的に採用されるようにすることができます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 血液疾患に対するin vivo RNAベース遺伝子編集モデルの開発調査の増加が市場成長を牽引すると予想されます。
    • 悪性非ホジキンリンパ腫に対するPD-1ノックアウトによるCD19を標的とした同種CRISPRベースCAR-T療法の臨床成績の増加が市場成長を促進すると予想されます。
  • 抑制要因
    • 希少作物における遺伝子編集における規制課題が市場成長の妨げになると予想されます。
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• パイプライン分析

第6章 COVID-19分析

第7章 タイプ別

• CRISPR-Cas9（Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9）
• TALEN（Transcription Activator-Like Effector Nucleases）
• ZFN（Zinc Finger Nucleases）

第8章 応用分野別

• 医療治療
• 医薬品開発
• 農業・食品生産
• 生物学研究
• 合成生物学
• その他

第9章 エンドユーザー別

• バイオテクノロジー・製薬企業
• 学術・研究機関
• CRO（医薬品開発業務受託機関）
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な動向と戦略

第12章 企業プロファイル

• CRISPR Therapeutics
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Intellia Therapeutics
• Precision BioSciences
• Synthego
• Sangamo Therapeutics
• Cellectis
• Precigen
• GenScript
• Editas Medicine
• Caribou Biosciences

第13章 付録

Overview

Global gene editing tools market reached US$ 5.8 billion in 2022 and is expected to reach US$ 22.0 billion by 2030 growing with a CAGR of 18.7% during the forecast period 2023-2030.

CRISPR Therapeutics, and Vertex Pharmaceuticals, are part of the Kelly CRISPR & Gene Editing Technology ETF and are expected to launch the first-ever U.S.-marketed treatment based on CRISPR this year. The treatment, called Exa-cel, is a gene-editing cure for sickle cell disease and beta-thalassemia and could become the first-ever CRISPR-based medicine to hit the market.

The FDA has granted the drug a priority review for sickle cell disease, with a decision expected by December 8, 2023. If approved, this would be a significant milestone in the Life Sciences Industrial Revolution, which could set expectations for future gene-editing programs. Vertex is leading the global development, manufacturing, and commercialization of Exa-cel and is splitting program costs and profits worldwide 60/40 with CRISPR Therapeutics.

Gene editing tools are revolutionary technologies that empower scientists to precisely modify the genetic material of living organisms. These tools, which include CRISPR-Cas9, TALENs, and ZFNs, allow researchers to insert, delete, or alter specific DNA sequences with an unprecedented level of accuracy.

This breakthrough has far-reaching implications across various fields such as medicine, agriculture, and biotechnology, as it allows for the development of targeted therapies, the creation of genetically modified organisms, and the advancement of scientific knowledge. Gene editing tools hold immense potential to address genetic diseases, enhance crop yields, and drive innovations that shape the future of genetics and personalized medicine.

Furthermore, the rapid advancement and adoption of gene editing tools across various industries, and rising investment by the market players are the factors expected to drive the market over the forecast period.

Dynamics

Increasing Research in Developing in vivo RNA-based Gene Editing Model for Blood Disorders is Expected to Drive the Market Growth

On July 27, 2023, a team of researchers at the Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania successfully created a model for administering gene editing tools directly to the body to treat blood disorders. This development could pave the way for the direct modification of diseased blood cells in the body, leading to a significant breakthrough in the treatment of blood disorders.

In their experiments, the researchers used CRISPR-based gene editing tools to modify the genes of blood cells in mice, and the results were promising. This breakthrough is particularly significant because it may make ex vivo gene editing unnecessary. This process requires removing cells from the body, editing them in a lab, and then returning them to the body. In vivo gene editing, on the other hand, is a potentially more efficient and less invasive approach to treating blood disorders.

Hence, owing to the above mentioned factors, the market is expected to drive during the forecast period.

Increasing Clinical Results of Allogeneic CRISPR-Based CAR-T Therapy Targeting CD19 with PD-1 Knockout for Aggressive Non-Hodgkin's Lymphomas is Expected to Drive the Market Growth.

In December 2022, Caribou Biosciences released positive results from their trial in the US of an allogeneic CRISPR-based CAR-T therapy that targets CD19 in aggressive non-Hodgkin's lymphomas that are difficult to treat. The therapy also features a second genetic modification that disables the PD-1 gene, which cancer cells sometimes use to evade the immune system. The treatment was generally well-tolerated and had an acceptable safety profile.

In a phase 1 trial with 6 participants, all of them initially showed total remission. Two of the participants had no signs of the disease a year later and are still being monitored by the trial. Caribou Biosciences' product has been granted RMAT (Regenerative Medicine Advanced Therapy) and Fast Track designations by the FDA, based on this initial data. This is a groundbreaking development in the field of gene editing and cancer treatment.

The therapy's success in targeting CD19 and deactivating PD-1 has demonstrated promising safety and efficacy results in a phase 1 trial for non-Hodgkin's lymphomas. The ability to modify genes using CRISPR technology opens up new possibilities for personalized and targeted cancer therapies. More research and clinical trials will be required to confirm these findings and determine the long-term effectiveness of this approach.

The field of gene editing is constantly advancing and this groundbreaking therapy has the potential to transform cancer care with personalized and targeted treatments. Further research and clinical trials will be crucial in establishing the long-term effectiveness of this therapy and ushering in a new era of precision medicine for cancer patients.

Regulatory Challenges in Gene Editing in Orphan Crops are Expected to Hamper the Market Growth.

Gene editing in crops is subject to varying regulatory environments across countries and regions, which can hinder the adoption and implementation of gene editing technologies in orphan crops. Certain orphan crops may face additional regulatory obstacles due to their unique genetic makeups or limited commercial value.

For instance, the European Union (EU) has a stringent approach to regulating gene-edited crops and food, effectively prohibiting their introduction. In contrast, the United States (US) has a more lenient regulatory framework. Such differences pose challenges for companies and researchers operating across different regions.

The EU's strict regulations stem from the European Court of Justice's (ECJ) 2018 ruling that gene editing must be regulated under the 2001 GMO Directive, which restricts genetically modified crops that use genes from another species (e.g., transgenic crops). Thus, gene-edited crops and food are banned in the EU.

However, in September 2022, EU agriculture ministers discussed revising the rules on gene editing, acknowledging the benefits of precision techniques that enable easier and faster modification of a plant's DNA (cisgenics). Therefore, the varying regulatory frameworks across different countries and regions, such as the EU and the US, can pose challenges to the widespread adoption and implementation of gene editing technologies in crops. Streamlining regulations through harmonization can aid in the efficient development and commercialization of gene-edited crops, making them more accessible and adopted globally.

Segment Analysis

The global gene editing tools market is segmented based on type, application end-user, and region.

CRISPR-Cas9, which stands for "Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9," is a revolutionary gene editing technology that has transformed genetic research and applications. Originally discovered as a natural defense mechanism in bacteria against viral infections, scientists harnessed this system to create a powerful tool for precisely modifying DNA sequences in various organisms.

CRISPR-Cas9's ease of use, affordability, and applicability across a wide range of organisms have democratized gene editing, allowing researchers to tackle questions that were once challenging or impossible to address. While its potential is immense, ethical considerations and the need for precision and safety continue to be important aspects of its utilization.

Furthermore, on September 16, 2022, Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, announced positive interim results from an ongoing Phase 1/2 clinical study of NTLA-2002, its second in vivo genome editing candidate.

NTLA-2002 is a systemically administered CRISPR candidate being developed for hereditary angioedema (HAE) and is designed to knock out the KLKB1 gene in liver cells, thereby reducing the production of kallikrein protein. The uncontrolled activity of kallikrein is responsible for the overproduction of bradykinin, which leads to the recurring, debilitating, and potentially fatal swelling attacks that occur in people living with HAE. The interim data were shared today in an oral presentation at the 2022 Bradykinin Symposium held in Berlin, Germany.

Additionally, on June 14, 2022, the abstract was presented at the European Hematology Association (EHA) Congress, a group of researchers that includes Children's Hospital of Philadelphia (CHOP) presented new data on an investigational therapy for transfusion-dependent beta-thalassemia (TDT) and severe sickle cell disease (SCD). The one-time treatment, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, showed continued benefits at up to three years after administration, with a safety profile as expected for autologous transplant and potentially much safer than allogeneic transplant (from a donor).

The abstract provides new data from two clinical trials on exa-cel (exagamglogene autotemcel), formerly known as CTX001, a one-time treatment that utilizes CRISPR gene editing to boost the production of fetal hemoglobin to correct the defective gene for hemoglobin associated with both diseases. Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Penetration

North America Accounted for Approximately 43.7% of the Market Share in 2022, Owing to the Investing in Gene-Editing Stocks, Partnerships among Market Players, and the Developement of a New Gene-Editing System

North America is expected to hold the largest market share over the forecast period. Owing to the development of new gene-editing systems, increasing investment in gene-editing stocks, and partnerships among market players.

For instance, in February 2023, Moderna announced a partnership with ElevateBio to expand its gene editing research. The collaboration will utilize Life Edit's proprietary gene editing technologies, such as base editing, along with Moderna's mRNA platform to create potentially permanent treatments for rare genetic diseases and other conditions.

Base editing is a tool that uses CRISPR technology to modify a single base in the DNA code. Moderna will provide funding for preclinical research studies conducted by the two companies, using Life Edit's CRISPR-based tools that enable precise modifications to the human genome. The partnership's objective is to develop innovative gene therapies for the future. This joint venture highlights the potential for advancements in gene-editing therapies and ongoing efforts in the field of gene editing.

Hence, owing to the above factors, the North America region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include CRISPR Therapeutics, Intellia Therapeutics, Precision BioSciences, Synthego, Sangamo Therapeutics, Cellectis, Precigen, GenScript, Editas Medicine, and Caribou Biosciences among others.

COVID-19 Impact Analysis

COVID-19 has moderately impacted the gene editing tools market. The urgency to understand and combat the virus led to rapid research and development. Gene editing tools played a crucial role in studying the virus's genetics, creating diagnostic tests, and investigating potential therapies. mRNA-based platforms, a type of gene editing technology, played a pivotal role in developing COVID-19 vaccines like Pfizer-BioNTech and Moderna.

This highlighted the potential of these tools in responding to emergent infectious diseases. Researchers repurposed existing gene editing techniques to develop diagnostic tests for detecting SARS-CoV-2, demonstrating the adaptability and versatility of these tools.

However, shutdowns and restrictions had an impact on laboratory work and gene editing research, particularly in non-COVID-related areas. This delay slowed down progress in various projects. Resources were redirected to COVID-19-related research, which strained funding and attention. This could potentially limit investments and advancements in gene editing projects unrelated to the pandemic.

Clinical trials for gene therapies, which often require rigorous testing, were affected by disruptions in patient recruitment, monitoring, and regulatory processes. Lockdowns also hindered collaboration and communication among researchers, delaying information sharing and slowing down the dissemination of new findings.

Russia Ukraine Conflict Analysis

The ongoing war between Russia and Ukraine may have negative effects on scientific research and technology, particularly on gene editing tools. If research institutions, universities, or laboratories in either country are impacted by the conflict, it could disrupt ongoing scientific research, including gene editing studies. The movement of researchers, availability of resources, and communication between international collaborators may be hindered, which could slow down the progress of gene editing projects.

During times of conflict, governments tend to prioritize funding for defense and security, which could result in reduced investment in other areas like scientific research. This may limit the availability of resources for gene editing research, including funding for equipment, facilities, and personnel.

Additionally, international collaboration is crucial to the advancement of gene editing tools, but the conflict could make it more challenging for researchers from different countries, including Russia and Ukraine, to collaborate effectively due to travel restrictions, political tensions, and communication challenges.

By Type

• CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9)
• Transcription Activator-Like Effector Nucleases (TALENs)
• Zinc Finger Nucleases (ZFNs)

By Application

• Medical Therapies and Treatments
• Drug Development
• Agriculture and Food Production
• Biological Research
• Synthetic Biology
• Others

By End User

• Biotech and Pharma Companies
• Academic and Research Institutes
• Contract Research Organization
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On March 21, 2022, Merck KGaA, a leading multinational pharmaceutical company, signed through its Life Science division, MilliporeSigma, a unique collaboration and license agreement with an Israeli AgTech company to demonstrate the utility of its proprietary CRISPR genome-editing tools in agricultural uses. The agreement licenses its foundational CRISPR intellectual property to Israeli BetterSeeds Ltd., a disruptive company that uses genome editing technology including CRISPR to develop new breeds of plants.
• On February 22, 2023, ElevateBio and Moderna joined forces to focus on the development of gene editing therapies using a tool called base editing. This tool can alter a single letter in the DNA code, and the partnership aims to speed up the development of new treatments. To achieve this, Moderna will provide funding for preclinical research led by Life Edit Therapeutics, a subsidiary of ElevateBio based in North Carolina. The research will use CRISPR technologies to create potentially permanent treatments for rare genetic diseases and other conditions. This partnership is part of Moderna's efforts to expand its gene editing portfolio, which uses technologies similar to those employed in its COVID-19 vaccines.

Why Purchase the Report?

• To visualize the global gene editing tools market segmentation based on type, application, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global gene editing tools market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global gene editing tools market report would provide approximately 61 tables, 61 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Application
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Research in Developing in vivo RNA-based Gene Editing Model for Blood Disorders is Expected to Drive the Market Growth.
    • 4.1.1.2. Increasing Clinical Results of Allogeneic CRISPR-Based CAR-T Therapy Targeting CD19 with PD-1 Knockout for Aggressive Non-Hodgkin's Lymphomas is Expected to Drive Market Growth.
  • 4.1.2. Restraints
    • 4.1.2.1. Regulatory Challenges in Gene Editing in Orphan Crops are Expected to Hamper the Market Growth.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Pipeline Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9) *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%
• 7.3. Transcription Activator-Like Effector Nucleases (TALENs)
• 7.4. Zinc Finger Nucleases (ZFNs)

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Medical Therapies and Treatments*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%
• 8.3. Drug Development
• 8.4. Agriculture and Food Production
• 8.5. Biological Research
• 8.6. Synthetic Biology
• 8.7. Others

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Biotech and Pharma Companies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Academic and Research Institutes
• 9.4. Contract Research Organization
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Product Benchmarking
• 11.3. Company Share Analysis
• 11.4. Key Developments and Strategies

12. Company Profiles

• 12.1. CRISPR Therapeutics*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Intellia Therapeutics
• 12.3. Precision BioSciences
• 12.4. Synthego
• 12.5. Sangamo Therapeutics
• 12.6. Cellectis
• 12.7. Precigen
• 12.8. GenScript
• 12.9. Editas Medicine
• 12.10. Caribou Biosciences

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us